NBY Stock Analysis: Buy, Sell, or Hold?
NBY - NovaBay Pharmaceuticals, Inc.
$1.95
0.36 (22.64%)
▲
5d:
+27.45%
30d:
+33.56%
90d:
-65.43%
WAIT
LOW Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 21, 2026
Get Alerted When NBY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: NBY is 18.2% above fair value ($1.65). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: NBY is 18.2% above fair value ($1.65). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: NBY is currently trading at $1.95, which is considered extended relative to its 30-day fair value range of $1.25 to $1.65.
Technical Outlook: Technically, NBY is in a uptrend. The price is approaching resistance at $1.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 22.6% recently.
Market Sentiment: NBY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $0.85. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NBY is in a uptrend. The price is approaching resistance at $1.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 22.6% recently.
Market Sentiment: NBY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $0.85. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$1.25 -
$1.65
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Price significantly overextended (+18.2% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+22.6%)
- BEARISH: Trading 56.4% above Wall St target ($0.85)
- WARNING: Recommendation downgraded due to 18.2% overvaluation
Fair Price Analysis
30-Day Fair Range
$1.25 -
$1.65
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$1.13
Resistance Level
$1.75
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
42.02
Wall Street Target
$0.85
(-56.4%)
Revenue Growth (YoY)
-78.7%
Share & Embed Analysis
Last updated: April 02, 2026 9:04 PM ET
Data refreshes hourly during market hours. Next update: 10:04 PM
Data refreshes hourly during market hours. Next update: 10:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBY showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 58 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$132 | 58 HOLD |
